Heron Therapeutics, Inc. (HRTX)

Stock Price: $15.76 USD 0.11 (0.70%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $15.60 -0.16 (-1.02%) Jul 10, 6:07 PM
Zacks Investment Research - 1 week ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Zacks Investment Research - 1 week ago

Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.

The Motley Fool - 1 week ago

Its non-opioid painkiller gets a rejection over non-clinical issues.

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

PRNewsWire - 1 week ago

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-clas...

The Motley Fool - 3 weeks ago

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.

Stocks mentioned: HRTX, NVAX
Benzinga - 1 month ago

Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.

The Motley Fool - 2 months ago

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Stocks mentioned: ABBV, ADVM, HRTX
Zacks Investment Research - 2 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 3 months ago

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

Stocks mentioned: HRTX, ICPT
Zacks Investment Research - 4 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...

Seeking Alpha - 4 months ago

Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension

Zacks Investment Research - 4 months ago

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Benzinga - 7 months ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND, PRTK, PTE, VKTX, XON, ZIOP
Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).

Seeking Alpha - 7 months ago

Heron Therapeutics: Looking Solid Heading Into 2020

Zacks Investment Research - 7 months ago

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 7 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 8 months ago

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 8 months ago

These two biotech stocks are poised for big gains next year.

Stocks mentioned: AMRN, HRTX
InvestorPlace - 9 months ago

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Stocks mentioned: FDX, HRTX, IMMU, KALV, VBIV
The Motley Fool - 9 months ago

A high-risk transformative move sent one of these stocks lower.

Stocks mentioned: AVT, HPQ, HRTX
Seeking Alpha - 9 months ago

The steep sell-off in biotech over the past two weeks has obscured some positive developments around Heron Therapeutics.

Zacks Investment Research - 9 months ago

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

The Motley Fool - 10 months ago

You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.

Stocks mentioned: AMZN, HRTX, WPM
Seeking Alpha - 11 months ago

Despite better than expected Q2 results, the stock of small biopharma Heron Therapeutics sits near 52-week lows.

GuruFocus - 11 months ago

The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and ...

Stocks mentioned: AMRN, HRTX
Zacks Investment Research - 11 months ago

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 7.35% and 18.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 11 months ago

These three biotech stocks might be outstanding buys right now.

Stocks mentioned: CELG, HRTX, IOVA
The Motley Fool - 11 months ago

Amarin and Heron Therapeutics could turn out to be outstanding bargains.

Stocks mentioned: AMRN, HRTX
Seeking Alpha - 1 year ago

Not all CRLs are created equal. Investors likely overreacted to the recent announcement of Heron’s Complete Response Letter.

The Motley Fool - 1 year ago

These stocks are bargains.

Stocks mentioned: CVS, HRTX, ILMN
Seeking Alpha - 1 year ago

The FDA gave Heron Therapeutics' HTX-011 drug a CRL after issues were noted with the CMC and non-clinical information portion of the application.

The Motley Fool - 1 year ago

Heron's falling share price last month turned out to be a bad omen.

Seeking Alpha - 1 year ago

Heron is a fundamentally sound company undergoing what is seemingly a temporary share price depreciation.

Zacks Investment Research - 1 year ago

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Heron's pain is Pacira's gain.

Stocks mentioned: HRTX, PCRX
Benzinga - 1 year ago

Heron Therapeutics Inc was in for a disappointment after the FDA knocked down its new drug application for its investigational compound for post-operative pain management.

Market Watch - 1 year ago

Shares of Heron Therapeutics Inc. fell 31% on Wednesday after the biotech said the FDA would not approve the new drug application for its pain-management drug HTX-011 in its present form.

Seeking Alpha - 1 year ago

HTX-011 has a good chance of FDA approval by its April 30, 2019 PDUFA date.

Seeking Alpha - 1 year ago

Due to its obscurity, Heron Therapeutics is enjoying robust fundamental developments yet its shares are trading at a significantly depressed valuation.

The Motley Fool - 1 year ago

April's about to shower biopharma investors with important updates that could move these stocks.

Stocks mentioned: ASMB, FGEN, GWPH, HRTX

Latest From StockTwits